Celerion Earns AAHRPP Full Reaccreditation for Five Years, Strengthening Commitment to Ethical Research Practices

LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leader in early clinical research, proudly announces its achievement of a full AAHRPP (Association for the Accreditation of Human Research Protection Programs) reaccreditation for five years by the Council on Accreditation of AAHRPP. Celerion is the only CRO headquartered in the USA to hold this distinguished accreditation. This prestigious recognition underscores Celerion's unwavering dedication to maintaining the highest ethical standards, safeguarding participant welfare, and fostering excellence in clinical research.

AAHRPP accreditation is a coveted distinction in the research industry, signifying that an organization upholds rigorous standards for human research protection. By achieving this reaccreditation, Celerion strengthens its position as an industry leader and its ongoing commitment to advancing groundbreaking clinical studies in a safe and ethical manner.

"This milestone represents the hard work and dedication of our entire team," said Phil Bach, Celerion’s Executive Vice President of Global Clinical Research. "We are deeply committed to upholding participant safety and the highest ethical standards in our research. Earning AAHRPP reaccreditation for five years reflects our steadfast focus on setting the benchmark for clinical research excellence and integrity. We are honored to receive this recognition and remain focused on making meaningful contributions to the field of clinical development."

The AAHRPP accreditation process is rigorous, requiring a comprehensive evaluation of an organization’s policies, practices, and commitment to continuous improvement in human research protection. This achievement reinforces Celerion’s capability to manage complex clinical programs while prioritizing the well-being of participants—an essential element of ethical research practices.

With over 50 years of experience in clinical research, Celerion has earned a global reputation for innovation and leadership. This reaccreditation not only validates the company’s dedication to regulatory compliance but also sets it apart as a trusted partner for sponsors seeking to conduct high-quality research.

About Celerion

Celerion, a global leader in early clinical research, offers clients expert-driven services that enable fast, informed decisions in drug development. With over 50 years of experience, Celerion specializes in Phase 1 studies, including first-in-human dose escalation, drug-drug interactions, cardiac safety, bioequivalence, metabolism, and pharmacokinetics in patient populations. Celerion also provides comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. For more information, visit www.celerion.com.